Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 8.01 (Other Events). ERAS-0015 showed 62% 8-week uORR in 2L+ KRAS G12X NSCLC patients at 16–32 mg QD, supporting accelerated expansion.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ERAS-0015 showed 62% 8-week uORR in 2L+ KRAS G12X NSCLC patients at 16–32 mg QD, supporting accelerated expansion
- PDAC activity reached 40% 14-week uORR at 16–32 mg QD, with 20 of 23 responders remaining on treatment
- 100% of patients at pharmacologically active doses achieved at least 75% KRAS G12X ctDNA reduction, including 5 of 14 with 100% reduction
- 24 mg and 32 mg QD selected as monotherapy expansion doses, with combination studies involving panitumumab underway
- Key risk: one Grade 3 pneumonitis case progressed to Grade 5 after supportive-care withdrawal; efficacy comparisons remain cross-study and preliminary
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.